{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:17:49Z","timestamp":1790741869077,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xops.2024.100628","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:52:58Z","timestamp":1728489178000},"page":"100628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation"],"prefix":"10.1016","volume":"5","author":[{"given":"Justis P.","family":"Ehlers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Cousins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia K.","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Abbruscato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prema","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schadlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Novalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek Y.","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parchue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Jin","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Suan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Pieramici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Shildkrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew T.","family":"Witmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelina","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Learned","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Pattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Khetpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Lee Sjatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2024.100628_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.xops.2024.100628_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archophthalmol.2009.58","article-title":"Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments","volume":"127","author":"Rein","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2024.100628_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing disease burden and progression of geographic atrophy secondary. To age-related macular degeneration","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100628_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100628_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100628_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101781","article-title":"Complement activation, lipid metabolism, and mitochondrial injury: converging pathways in age-related macular degeneration","volume":"37","author":"Tan","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.xops.2024.100628_bib7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbalip.2016.07.013","article-title":"Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration","volume":"1862","author":"Handa","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.xops.2024.100628_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1159\/000517794","article-title":"The use of neuroprotective agents in treating geographic atrophy","volume":"64","author":"Scholl","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.xops.2024.100628_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.oret.2022.05.002","article-title":"Impact of baseline quantitative OCT features on response to risuteganib for the treatment of dry age-related macular degeneration: the importance of outer retinal integrity","volume":"6","author":"Abraham","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100628_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3928\/23258160-20211210-01","article-title":"Risk classification for progression to subfoveal geographic atrophy in dry age-related macular degeneration using machine learning-enabled outer retinal feature extraction","volume":"53","author":"Sarici","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2024.100628_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjophthalmol-2015-307105","article-title":"Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography","volume":"100","author":"Itoh","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100628_bib12","first-page":"396","article-title":"Local anatomic precursors to new-onset geographic atrophy in age-related macular degeneration as defined on OCT","volume":"5","author":"Pasricha","year":"2021","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.xops.2024.100628_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajo.2022.06.023","article-title":"Comparison of fundus autofluorescence versus optical coherence tomography\u2013based evaluation of the therapeutic response to pegcetacoplan in geographic atrophy","volume":"244","author":"Mai","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100628_bib14","series-title":"Exploration of Machine Learning-Enhanced Compartmental Retinal Integrity Assessment for Progression Risk and Treatment Response in the GATHER1 Study","author":"Ehlers","year":"2022"},{"key":"10.1016\/j.xops.2024.100628_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.oret.2022.08.003","article-title":"Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning","volume":"7","author":"Vogl","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100628_bib16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamaophthalmol.2020.2914","article-title":"Progression of photoreceptor degeneration in geographic atrophy secondary to age-related macular degeneration","volume":"138","author":"Pfau","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100628_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/IAE.0000000000001002","article-title":"Visual function measures in early and intermediate age-related macular degeneration","volume":"36","author":"Chandramohan","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100628_bib18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archopht.121.11.1621","article-title":"Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11","volume":"121","author":"Bressler","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2024.100628_bib19","first-page":"543","article-title":"Ellipsoid zone integrity and visual function in dry age-related macular degeneration","volume":"14","author":"Yordi","year":"2024","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.xops.2024.100628_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Opththamology"},{"key":"10.1016\/j.xops.2024.100628_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ophtha.2008.03.009","article-title":"Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration","volume":"115","author":"Sunness","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.xops.2024.100628_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1167\/iovs.61.5.63","article-title":"Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration","volume":"61","author":"K\u00fcnzel","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100628_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231748","article-title":"Detecting vision loss in intermediate age-related macular degeneration: a comparison of visual function tests","volume":"15","author":"Pondorfer","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100628_bib24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1152\/japplphysiol.00591.2011","article-title":"Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy","volume":"111","author":"Min","year":"2011","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.xops.2024.100628_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/acel.12102","article-title":"Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice","volume":"12","author":"Siegel","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.xops.2024.100628_bib26","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xops.2024.100628_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206","article-title":"Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure","volume":"9","author":"Sabbah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.xops.2024.100628_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tem.2021.01.006","article-title":"Cardiolipin, mitochondria, and neurological disease","volume":"32","author":"Falabella","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.xops.2024.100628_bib29","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3892\/mmr.2017.6271","article-title":"Protective effect of mitochondriatargeted peptide MTP131 against oxidative stressinduced apoptosis in RGC5 cells","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.xops.2024.100628_bib30","series-title":"SS31 Protects human RPE cells from oxidative damage and reduces laser-induced choroidal neovascularization","author":"Liang","year":"2010"},{"key":"10.1016\/j.xops.2024.100628_bib31","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1167\/iovs.11-7524","article-title":"Mitochondria-targeted peptide MTP-131 alleviates mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells","volume":"52","author":"Chen","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100628_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bbrc.2010.11.122","article-title":"Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells","volume":"404","author":"Li","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.xops.2024.100628_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2174\/15665240113139990049","article-title":"Mitochondria-targeted antioxidant peptide SS31 protects the retinas of diabetic rats","volume":"13","author":"Huang","year":"2013","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.xops.2024.100628_bib34","first-page":"701","article-title":"A\u00a0mitochondrial therapeutic reverses visual decline in mouse models of diabetes","volume":"8","author":"Alam","year":"2015","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.xops.2024.100628_bib35","article-title":"Phase 1 clinical trial of elamipretide in intermediate age-related macular degeneration and high-risk drusen","volume":"1","author":"Allingham","year":"2022","journal-title":"Opththamol Sci"},{"key":"10.1016\/j.xops.2024.100628_bib36","article-title":"Phase 1 clinical trial of elamipretide in dry age-related macular degeneration and noncentral geographic atrophy","volume":"2","author":"Mettu","year":"2022","journal-title":"Opththalmol Sci"},{"key":"10.1016\/j.xops.2024.100628_bib37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.oret.2024.02.010","article-title":"Compartmental exudative dynamics in neovascular age-related macular degeneration: volumetric outcomes and impact of volatility in a phase III clinical trial","volume":"8","author":"Ehlers","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100628_bib38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ophtha.2019.09.035","article-title":"Incomplete retinal pigment epithelial and outer atrophy (iRORA) in age-related macular degeneration: CAM Report 4","volume":"127","author":"Guymer","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100628_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral de Guimaraes","year":"2022","journal-title":"Br J Opthalmol"},{"key":"10.1016\/j.xops.2024.100628_bib40","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100628_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.oret.2019.06.010","article-title":"Higher-order assessment of OCT in diabetic macular edema from the VISTA study: ellipsoid zone dynamics and the retinal fluid index","volume":"3","author":"Ehlers","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100628_bib42","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.oret.2021.02.012","article-title":"Longitudinal assessment of ellipsoid zone integrity, subretinal hyperreflective material, and subretinal pigment epithelium disease in neovascular age-related macular degeneration","volume":"5","author":"Ehlers","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100628_bib43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2024.100628_bib44","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2024.100628_bib45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100628_bib46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:46:21Z","timestamp":1772048781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914524001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666914524001647"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2024.100628","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2024.100628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100628"}}